Welcome to Dr. Elliott Antman's AHA Emerging Science™ Series.

AHA is proud to introduce a new program to further science collaboration hosted by Dr. Elliot Antman: The AHA Emerging Science™ Series webinars are one hour professional quality webinars held three times per year. Dr. Antman will host each webinar, which will have two 30 minute blocks, consisting of presentations of original research from the following categories:

  • Late Breaking Clinical Trials
  • Clinical Trial Updates of previously presented LBCTs
  • Late Breaking Basic Science
  • Major Bench-to-Bedside Advances
  • Major Conference Proceedings
  • Major Guidelines/Policy Statements

The live webinar events will be viewable from a computer or mobile phone, both live and on-demand. Attendees can ask questions electronically during the live event or post event. View the ESS Brochure here

Join us at the next event, or view this blog for past events.

Latest Posts

The American Heart Association has the solution through the Emerging Science Series (ESS), our live webinars which provide a year-round venue for science presentation on a fast-tracked basis.  Submit by Thursday, January 3rd and if your science is accepted, you will be presenting via live webinar on Wednesday, February 27th.  AHA has the best science, the best education and the best opportunities for presentation. ESS science submission opens Wednesday, December 12th!

AHA's Emerging Science Series is accepting submissions from 
Dec 12-Jan 3, 2013, 
 5 p.m. CDT (UTC -06) 


Posted by Alyson PON Editor on Dec 10, 2012 2:15 PM CST

New Antithrombotic Therapies - Crossing Vascular Beds and Reversing Their Effects
Presented: Wednesday, June 20, 2012
Posted by Alyson PON Editor on Jul 6, 2012 10:55 AM CDT

New Antithrombotic Therapies - Crossing Vascular Beds and Reversing Their Effects

Wednesday, June 20, 2012, noon - 1:05 p.m. CDT

Registration is closed




Robert O Bonow and Elliott Antman 


Alan T Hirsch, Minneapolis, MN, and Neil Zakai, Colchester, VT, and Cynthia Rutherford, Dallas, TX


Vorapaxar for Secondary Prevention in Patients with Peripheral Artery Disease: Results from the Peripheral Artery Disease Cohort of the TRA 2°P-TIMI 50 Trial

Marc P Bonaca, Boston, MA  


Discussion Q&A  



Reversal of Apixaban Induced Alterations of Hemostasis By Different Coagulation Factor Concentrates: Studies In Vitro With Circulating Human Blood

Gines Escolar, Barcelona, Spain  


Discussion Q&A 



Continuing Education Accreditation

Physicians, Nurses, Pharmacists and EMS Practitioners may earn continuing education credits.  For full CME/CE accreditation information on Emerging Science Series webinars, please visit learn.heart.org.


Posted by Alyson PON Editor on Jun 20, 2012 8:30 AM CDT

AHA's Emerging Science™ Series is accepting submissions until May 9, 2012, 5 p.m. CDT (UTC -05).


For learning objectives and submission guidelines, please click these links:
ESS Learning Objectives & ESS Science Submission Guidelines

Posted by Alyson PON Editor on Apr 27, 2012 9:54 AM CDT

Protecting Cerebrovascular Function - From Translational Science to Clinical Trials

Wednesday, April 25, 2012, Noon–1:05 p.m.

  • Elliott Antman
  • Robert Harrington
  • Robert Bonow
  • John Murkin
  • Jeffrey Weitz 
  • Mark Clay
Posted by Alyson PON Editor on Apr 27, 2012 9:44 AM CDT

Protecting Cerebrovascular Function - From Translational Science to Clinical Trials

Wednesday, April 25, 2012, Noon–1:05 p.m.

Presentation Topics: 
  1. Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Analysis from the ROCKET AF Trial  
    Presenter: Jonathan P. Piccini, Duke Clinical Res Inst, Duke Univ Medical Ctr, Durham, NC
    View abstract   |   Science News Summary 
  2. Cerebrovascular Autoregulation Impairment is Associated with Elevations in Plasma Glial Fibrillary Acidic Protein During Congenital Heart Surgery  
    Presenter: Ronald B. Easley, Baylor Coll of Med, Houston, TX
    View manuscript   |   Science News Summary
Posted by Alyson PON Editor on Apr 24, 2012 9:32 AM CDT
ESS11_Pslides_McAllister_imageFirst Human Use of an Allogeneic Tissue Engineered Vascular Graft
Description: A first-in-human study to test the feasibility of an allogeneic tissue-engineered vascular graft
Presenter: Todd N. McAllister, Novato, Calif.

Posted by Alyson PON Editor on Mar 9, 2012 12:42 PM CST

Presentation Topics:

1) Mitral Valve Annuloplasty in Addition to Coronary Artery Bypass Grafting Improves Functional Capacity and Promotes Reverse Left Ventricular Remodelling: Preliminary Results of the Randomised Ischemic Mitral Evaluation Trial  
Presenter: K. M. John Chan, London, United Kingdom
View abstract   |   Science News Summary   

2) Relationship of National Institutes of Health Stroke Scale to 30-Day Mortality in Medicare Beneficiaries With Acute Ischemic Stroke  
Presenter: Gregg C. Fonarow, Los Angeles, Calif.
View manuscript   |   Science News Summary
Posted by Alyson PON Editor on Mar 8, 2012 5:44 PM CST

Most Recent Comments

I am intrigued by this exciting new AHA Emerging Science Series, and particularly interested to hear the discussion on the US subgroup analysis from PLATO.
I am very enthusiastic to hear more about tissue engineered vascular grafts. The science is quite provocative and the potential for clinical application is substantial!
As the Director of the Adult Invasive and Interventional Cardiology Program in Nassau, The Bahamas, I am excited to join the panel to discuss the implications of the PLATO US subgroup findings. Clearly dual antiplatelet therapy is at the center of the pharmacologic support for PCI and we need to understand the optimal regimen to protect our patients.
I am pleased to see a translational science presentation in this first webinar of the AHA Emerging Science Series. Using allogeneic fibroblasts to build a tissue engineered vascular graft is a creative approach to a common clinical problem. I look forward to learning more about how this was done and the results in the first in human experience.
The PLATO US substudy raises a number of important questions that will attract the attention of clinical trialists, interventional cardiologists, and vascular biologists. Should be an interesting discussion.